| Dr. Susan Rife Family Medicine Sc | |
|
10755 W 163 Place Orland Park IL 60467 | |
| (708) 873-1187 | |
| (708) 873-1204 |
| Full Name | Dr. Susan Rife Family Medicine Sc |
|---|---|
| Speciality | Family Medicine |
| Location | 10755 W 163 Place, Orland Park, Illinois |
| Authorized Official Name and Position | Susan Barbara Rife (PHYSICIAN OWNER) |
| Authorized Official Contact | 7088731187 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Dr. Susan Rife Family Medicine Sc 10755 W 163 Place Orland Park IL 60467 Ph: (708) 873-1187 | Dr. Susan Rife Family Medicine Sc 10755 W 163 Place Orland Park IL 60467 Ph: (708) 873-1187 |
| NPI Number | 1184602880 |
|---|---|
| Provider Enumeration Date | 01/04/2006 |
| Last Update Date | 04/04/2012 |
| Medicare PECOS PAC ID | 9931099363 |
|---|---|
| Medicare Enrollment ID | O20040318000635 |
News Archive
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today reported that it has completed enrolment of its COMPONENT Phase IIb study with vidofludimus, an oral inhibitor of IL-17 release, in rheumatoid arthritis (RA) patients. Data from the trial are expected to be announced in Q2 2011.
A program at Mayo Clinic using telemedicine technology is showing promise for patients with concussions in rural Arizona. A case study published in the December 2012 issue of Telemedicine and e-Health validates "teleconcussion" as a useful means to assess concussed patients.
Drug-induced liver disease (DILD), a potential complication seen with some medications, is usually not life-threatening, but may occasionally be more severe with a high mortality, requiring a liver transplant in selected cases.
PDL BioPharma, Inc. (PDL) today corrected its earlier-announced adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), to 155.396 shares of common stock per $1,000 principal amount, reflecting a conversion price of approximately $6.44 per share, effective December 9, 2011.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184602880 | NPI | - | NPPES |
| 036077841 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 036077841 (Illinois) | Primary |
| Provider Name | Susan B Rife |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1720067234 PECOS PAC ID: 5799678108 Enrollment ID: I20040207000130 |
News Archive
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today reported that it has completed enrolment of its COMPONENT Phase IIb study with vidofludimus, an oral inhibitor of IL-17 release, in rheumatoid arthritis (RA) patients. Data from the trial are expected to be announced in Q2 2011.
A program at Mayo Clinic using telemedicine technology is showing promise for patients with concussions in rural Arizona. A case study published in the December 2012 issue of Telemedicine and e-Health validates "teleconcussion" as a useful means to assess concussed patients.
Drug-induced liver disease (DILD), a potential complication seen with some medications, is usually not life-threatening, but may occasionally be more severe with a high mortality, requiring a liver transplant in selected cases.
PDL BioPharma, Inc. (PDL) today corrected its earlier-announced adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), to 155.396 shares of common stock per $1,000 principal amount, reflecting a conversion price of approximately $6.44 per share, effective December 9, 2011.
› Verified 8 days ago
| Provider Name | Marianne H Laff |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215916788 PECOS PAC ID: 6901799303 Enrollment ID: I20040207000383 |
News Archive
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today reported that it has completed enrolment of its COMPONENT Phase IIb study with vidofludimus, an oral inhibitor of IL-17 release, in rheumatoid arthritis (RA) patients. Data from the trial are expected to be announced in Q2 2011.
A program at Mayo Clinic using telemedicine technology is showing promise for patients with concussions in rural Arizona. A case study published in the December 2012 issue of Telemedicine and e-Health validates "teleconcussion" as a useful means to assess concussed patients.
Drug-induced liver disease (DILD), a potential complication seen with some medications, is usually not life-threatening, but may occasionally be more severe with a high mortality, requiring a liver transplant in selected cases.
PDL BioPharma, Inc. (PDL) today corrected its earlier-announced adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), to 155.396 shares of common stock per $1,000 principal amount, reflecting a conversion price of approximately $6.44 per share, effective December 9, 2011.
› Verified 8 days ago
| Provider Name | Mark E Mckeigue |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1962480657 PECOS PAC ID: 1850281056 Enrollment ID: I20040319000777 |
News Archive
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today reported that it has completed enrolment of its COMPONENT Phase IIb study with vidofludimus, an oral inhibitor of IL-17 release, in rheumatoid arthritis (RA) patients. Data from the trial are expected to be announced in Q2 2011.
A program at Mayo Clinic using telemedicine technology is showing promise for patients with concussions in rural Arizona. A case study published in the December 2012 issue of Telemedicine and e-Health validates "teleconcussion" as a useful means to assess concussed patients.
Drug-induced liver disease (DILD), a potential complication seen with some medications, is usually not life-threatening, but may occasionally be more severe with a high mortality, requiring a liver transplant in selected cases.
PDL BioPharma, Inc. (PDL) today corrected its earlier-announced adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), to 155.396 shares of common stock per $1,000 principal amount, reflecting a conversion price of approximately $6.44 per share, effective December 9, 2011.
› Verified 8 days ago
| Provider Name | Kimberly M Mckinnon |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1124257241 PECOS PAC ID: 1456502285 Enrollment ID: I20121103000047 |
News Archive
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today reported that it has completed enrolment of its COMPONENT Phase IIb study with vidofludimus, an oral inhibitor of IL-17 release, in rheumatoid arthritis (RA) patients. Data from the trial are expected to be announced in Q2 2011.
A program at Mayo Clinic using telemedicine technology is showing promise for patients with concussions in rural Arizona. A case study published in the December 2012 issue of Telemedicine and e-Health validates "teleconcussion" as a useful means to assess concussed patients.
Drug-induced liver disease (DILD), a potential complication seen with some medications, is usually not life-threatening, but may occasionally be more severe with a high mortality, requiring a liver transplant in selected cases.
PDL BioPharma, Inc. (PDL) today corrected its earlier-announced adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), to 155.396 shares of common stock per $1,000 principal amount, reflecting a conversion price of approximately $6.44 per share, effective December 9, 2011.
› Verified 8 days ago
News Archive
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today reported that it has completed enrolment of its COMPONENT Phase IIb study with vidofludimus, an oral inhibitor of IL-17 release, in rheumatoid arthritis (RA) patients. Data from the trial are expected to be announced in Q2 2011.
A program at Mayo Clinic using telemedicine technology is showing promise for patients with concussions in rural Arizona. A case study published in the December 2012 issue of Telemedicine and e-Health validates "teleconcussion" as a useful means to assess concussed patients.
Drug-induced liver disease (DILD), a potential complication seen with some medications, is usually not life-threatening, but may occasionally be more severe with a high mortality, requiring a liver transplant in selected cases.
PDL BioPharma, Inc. (PDL) today corrected its earlier-announced adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), to 155.396 shares of common stock per $1,000 principal amount, reflecting a conversion price of approximately $6.44 per share, effective December 9, 2011.
› Verified 8 days ago
Hellodoc Care Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 14150 Creek Crossing Dr, Orland Park, IL 60467 Phone: 708-369-4215 | |
Orland Primary Care Specialists Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 16660 107th St, Orland Park, IL 60467 Phone: 708-403-8500 Fax: 708-364-7080 | |
Midwest Obstetrisc & Gynecology Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7714 W 159th St, Orland Park, IL 60462 Phone: 708-429-2020 | |
Tj Siddiqui Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 11113 Woodstock Dr, Orland Park, IL 60467 Phone: 708-351-0292 | |
Vijayalakshmi Thota Do Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 15300 West Ave, Suite 303, Orland Park, IL 60462 Phone: 708-349-6713 | |
Sterling Primary Endocrine Care Associates S.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 14544 John Humphrey Dr, Orland Park, IL 60462 Phone: 708-460-7990 Fax: 708-460-7917 | |
John F Olivieri Md Sc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 14315 108th Ave, Suite 230, Orland Park, IL 60467 Phone: 708-966-9948 Fax: 708-364-8000 |